Prostate neoplasm
MONDO:0021259A neoplasm (disease) that involves the prostate gland.
Also known as: neoplasm of prostate, neoplasm of prostate gland, neoplasm of the prostate, prostate gland neoplasm, prostate gland neoplasm (disease), prostate gland tumor, prostate gland tumour, prostate tumor
3585 clinical trials for this condition and its sub-types, 124 tagged with Prostate neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Prostate neoplasm
-
Prostate cancer 1,913 trials · 2,217 incl. sub-types
5 sub-types
- Prostate carcinoma 394 trials · 1,321 incl. sub-types Sub-types →
- Prostate cancer, hereditary 1 trial · 4 incl. sub-types Sub-types →
- Malignant prostate phyllodes tumor 0 trials
- Prostate lymphoma 0 trials
- Prostate sarcoma 0 trials Sub-types →
-
Prostate neuroendocrine neoplasm 20 trials · 25 incl. sub-types
1 sub-type
- Prostate small cell carcinoma 9 trials
-
Prostate intraepithelial neoplasia 2 trials
1 sub-type
-
Benign neoplasm of prostate 0 trials
4 sub-types
- Benign prostate phyllodes tumor 0 trials
- Fibroma of prostate 0 trials
- Prostate leiomyoma 0 trials
- Prostatic adenoma 0 trials
-
Prostate phyllodes tumor 0 trials
2 sub-types
- Benign prostate phyllodes tumor 0 trials
- Malignant prostate phyllodes tumor 0 trials
Most studied deeper sub-types
-
Can a Cancer-Targeting drug slow advanced prostate cancer?
Disease control Not yet recruitingThis phase 3 trial tests whether risvutatug rezetecan, an antibody-drug conjugate that delivers a toxin directly to prostate cancer cells, can slow or shrink tumors better than standard hormone therapy. About 684 men with metastatic castration-resistant prostate cancer will recei…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Radiation boost may extend Drug-Free time in prostate cancer recurrence
Disease control Not yet recruitingThis trial tests whether adding targeted radiation to standard hormone therapy can help men with recurring prostate cancer stay off cancer drugs longer. Men with a rising PSA and 1 to 5 metastases will receive either hormone therapy alone or hormone therapy plus radiation to the …
Phase 3 • Sponsor: Ente Ospedaliero Cantonale, Bellinzona • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
Disease control Not yet recruitingThis study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…
Phase 2 • Sponsor: GV20 Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New Ultra-Strong MRI could spot prostate cancer without dye
Diagnosis Not yet recruitingThis study compares a new, stronger 7 Tesla MRI to the standard 3 Tesla MRI for finding suspicious spots in the prostate. Researchers want to see if the stronger scanner can detect problems more clearly and possibly without using a contrast dye. About 200 men will get both scans …
Sponsor: Assaf-Harofeh Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
Quantum leap in cancer detection: AI blood test could slash unnecessary biopsies
Diagnosis Not yet recruitingThis study is developing a new blood test that combines quantum sensors and artificial intelligence to detect prostate cancer. Researchers will analyze DNA fragments in blood samples from 1100 men to train an AI model. The goal is to create a non-invasive, accurate diagnostic too…
Sponsor: Shanghai Changzheng Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 07:59 UTC
-
Can a simple WhatsApp message save lives? chile tests new screening nudge
Knowledge-focused Not yet recruitingThis study will send different types of WhatsApp messages to 235,000 people in Chile who are due for cancer or chronic disease screenings. Researchers want to see if the way a message is worded (basic, risk-focused, or peace-of-mind) and whether it mentions one test or both tests…
Sponsor: University of Chile • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC